Akums Drugs & Pharmaceuticals has announced a new partnership with Canada’s Triple Hair Group. This collaboration focuses on the exclusive licensing of a patented topical treatment for androgenic alopecia in the Indian market.
The innovative formulation combines three unique medications to address alopecia, a common condition that affects millions both in India and around the globe.
The newly licensed topical solution aims to provide a comprehensive approach to hair care. It is designed to prevent hair loss, stimulate new hair growth, and improve hair thickness and density. This all-in-one solution targets those dealing with hair thinning and baldness.
This advanced formula offers a convenient and effective option for users who prefer topical treatments. It has the potential to enhance adherence and improve results for individuals facing hair loss.
Sanjeev Jain, Managing Director of Akums, stated, “Our collaboration with Triple Hair is a major step in expanding our dermatology portfolio and delivering innovative and effective hair care solutions in India.”
Jean-Philippe Gravel, CEO of Triple Hair, added, “A key benefit of this partnership is Akums’ direct involvement in the regulatory process, including an upcoming Phase III clinical trial in India. We plan to begin this process in the next few weeks, aiming to commercialize Therapy-07 in India as soon as possible.”
Related Topics: